Advances in the Research of Pathogenesis and Treatment of Mycosis Fungoides

( views:, downloads: )
Author:
ZHANG Si-ping()
ZHU Yi-yuan()
Journal Title:
INTERNATIONAL JOURNAL OF DERMATOLOGY AND VENEREOLOGY
Issue:
Volume 32, Issue 01, 2006
DOI:
Key Word:

Abstract´╝Ü

  • [1]Kansas GS.Selectins and their ligands:current concepts and controversies.Blood,1996,88:3259-3287.
  • [2]Ferenczi K,Fuhlbrigge RC,Pinkus J,et al.Increased CCR4 expression in cutaneous T cell lymphoma.J Invest Dermatol,2002,119:1405-1410.
  • [3]Zoi-Toli O,Vermeer MH,De Vries E,et al.Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL):association between lack of Fas expression and aggressive types of CTCL.Br J Dermatol,2000,143:313-319.
  • [4]Rook AH,Vowels BR,Jaworsky C,et al.The immunopathogenesis of cutaneous T-cell lymphoma.Abnormal cytokine production by Sezary T cells.Arch Dermatol,1993,129:486-489.
  • [5]Mao X,Orchard G,Lillington DM,et al.Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas.Blood,2003,101:1513-1519.
  • [6]Scarisbrick JJ,Woolford AJ,Russell-Jones R,et al.Allelotyping in mycosis fungoides and Sezary syndrome:common regions of allelic loss identified on 9p,10q,and 17p.J Invest Dermatol,117:663.
  • [7]Navas IC,Algara P,Mateo M,et al.pl6(INK4a) is selectively silenced in the tumoral progression of mycosis fungoides.Lab Invest,2002,82:123-132.
  • [8]Garatti SA,Roscetti E,Trecca D,et al.bcl-1,bcl-2,p53,c-myc,and lyt-10 analysis in cutaneous lymphomas.Recent Results Cancer Res,1995,139:249-261.
  • [9]Herrmann JJ,Roenigk HH Jr,Hurria A,et al.Treatment of mycosis fungoides with photochemotherapy (PUVA):long-term follow-up.J Am Acad Dermatol,1995,33(2 Pt 1):234-242.
  • [10]Stern RS,Bolshakov S,Nataraj AJ,et al.p53 mutation in nonmelanoma skin cancers occurring in psoralen ultraviolet a-treated patients:evidence for heterogeneity and field cancerization.J Invest Dermatol 2002,119:522-526.
  • [11]Diederen PV,van Weelden H,Sanders C J,et al.Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides:a retrospective study.J Am Acad Dermatol,2003,48:2159.
  • [12]Jones GW,Rosenthal D,Wilson LD.Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the Sezary syndrome).Cancer,1999,85:1985-1995.
  • [13]Von Hoff DD,Dahlberg S,Hartstock RJ,et al.Activity of fludarabine monophosphate in patients with advanced mycosis fungoides:a Southwest Oncology Group study.J Natl Cancer Inst,1990,82:1353-1355.
  • [14]Dolan ME,McRae BL,Ferries-Rowe E,et al.O6-alkylguanine-DNA alkyltransferase in cutaneous T-cell lymphoma:implications for treatment with alkylating agents.Clin Cancer Res,1999,5:2059-2064.
  • [15]Wollina U,Graefe T,Karte K.Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin.J Am Acad Dermatol,2000,42(1 Pt 1):40-46.
  • [16]Zhang C,Hazarika P,Ni X,et al.Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells:relevance to mechanism of therapeutic action.Clin Cancer Res,2002,8:1234-1240.
  • [17]Talpur R,Ward S,Apisarnthanarax N,et al.Optimizing bexarotene therapy for cutaneous T-cell lymphoma.J Am Acad Dermatol,2002,47:672-684.
  • [18]Breneman D,Duvic M,Kuzel T,et al.Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma.Arch Dermatol,2002,138:325-332.
  • [19]Chiarion-Sileni V,Bononi A,Fornasa CV,et al.Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma.Cancer,2002,95:569-575.
  • [20]Yoo EK,Rook AH,Elenitsas R,et al.Apoptosis induction of ultraviolet light A and photochemotherapy in cutaneous T-cell Lymphoma:relevance to mechanism of therapeutic action.J Invest Dermatol,1996,107:235-242.
  • [21]Gottlieb SL,Wolfe JT,Fox FE,et al.Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa:a 10-year experience at a single institution.J Am Acad Dermatol,1996,35:946-957.
  • [22]Foss FM.DAB(389)IL-2 (ONTAK):a novel fusion toxin therapy for lymphoma.Clin Lymphoma,2000,1:110-116.
  • [23]Rook AH,Wood GS,Yoo EK,et al.Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses.Blood,1999,94:902-908.
  • [24]Zaki MH,Wysocka M,Everetts SE,et al.Synergistic enhancement of cell-mediated immunity by interleukin-12 plus interleukin-2:basis for therapy of cutaneous T cell lymphoma.J Invest Dermatol,2002,118:366-371.
  • [25]Pawson R,Dyer M J,Barge R,et al.Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.J Clin Oncol,1997,15:2667-2672.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn